Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 2(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04281186Completed

Retinal and Cognitive Dysfunction in Type 2 Diabetes

Role: collaborator

NCT04527107Phase 2Completed

A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema

Role: lead

NCT05063734Phase 2Terminated

A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.

Role: lead

NCT00702494Phase 1Completed

Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours

Role: collaborator

NCT03499223Phase 2Completed

A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)

Role: lead

All 5 trials loaded